Dasatinib treatment for Philadelphia chromosome-positive Leukemias: practical considerations
Date
2009
Authors
Khoury, H.
Guilhot, F.
Hughes, T.
Kim, D.
Cortes, J.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Cancer, 2009; 115(7):1381-1394
Statement of Responsibility
Hanna Jean Khoury, François Guilhot, Timothy P. Hughes, Dong-Wook Kim and Jorge E. Cortes
Conference Name
Abstract
Dasatinib is a highly potent Bcr-Abl inhibitor that is approved for the treatment of imatinib-resistant or -intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Across a series of phase 2 and 3 trials, dasatinib was associated with durable treatment responses in all phases of the disease and was well tolerated. For this article, the authors reviewed available information on specific side effects associated with the use of dasatinib. On the basis of more than 2 years' experience of dasatinib treatment during clinical trials, they provide practical recommendations for side-effect management.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright © 2009 American Cancer Society